Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia

Novak, Urban; Grob, T. J.; Baskaynak, G.; Peters, U. R.; Aebi, Stefan; Zwahlen, D.; Tschan, Mario; Kreuzer, K.-A.; Oppliger Leibundgut, Elisabeth; Cajot, J.-F.; Tobler, Andreas; Fey, Martin (2001). Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia. Annals of oncology, 12(7), pp. 981-986. Oxford University Press 10.1023/A:1011153206003

[img] Text
Annals Oncology_Novak 01.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy
[img]
Preview
Text
12-7-981.pdf - Other
Available under License Publisher holds Copyright.

Download (1MB) | Preview

The p73 protein shares structural and functional similarities with the tumour-suppressor p53, but its role in neoplastic transformation is unknown. Alternative splicing leads to the expression of at least nine p73 C-terminal mRNA splice variants (alpha, beta, gamma, delta, epsilon, zeta, eta, eta1, theta). In this survey, we analyse the expression of p73 by real-time quantitative RT-PCR, its known C-terminal variants with an RT-PCR-Southern technique and by Western blot in samples of 51 patients with B-CLL, normal B lymphocytes from eight individuals, and five haematopoetic cell lines. p73alpha protein expression positively correlated with higher risk B-CLL stages (P = 0.046). Total p73 mRNA expression was higher (P = 0.01) and p73alpha protein more frequently detected (P = 0.008) in B-CLL compared with normal CD19+-B-lymphocytes. p73 C-terminal mRNA variants were expressed both in B-CLL and in normal B-lymphocytes, but their expression was biased since the gamma (P = 0.041), the theta (P < 0.001), and the eta variant (P = 0.033) prevailed in normal B-lymphocytes. In summary, we conclude that the accumulation of p73, the expression pattern of particular p73 variants and its link to progression may play a distinct role in the molecular pathology B-CLL.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Med. Onkologie / Hämatologie (Erw.)
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Med. Onkologie / Hämatologie (Erw.)

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Unit Childrens Hospital > Forschungsgruppe Hämatologie (Erwachsene)
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR)
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology
04 Faculty of Medicine > Service Sector > Institute of Pathology
04 Faculty of Medicine > Service Sector > Institute of Pathology > Tumour Pathology

UniBE Contributor:

Novak, Urban; Aebi, Stefan; Tschan, Mario; Oppliger Leibundgut, Elisabeth; Tobler, Andreas and Fey, Martin

Subjects:

600 Technology > 610 Medicine & health
500 Science > 570 Life sciences; biology

ISSN:

0923-7534

Publisher:

Oxford University Press

Language:

English

Submitter:

Mario Tschan

Date Deposited:

24 Nov 2017 16:46

Last Modified:

27 Apr 2018 10:09

Publisher DOI:

10.1023/A:1011153206003

PubMed ID:

11521806

BORIS DOI:

10.7892/boris.85990

URI:

https://boris.unibe.ch/id/eprint/85990

Actions (login required)

Edit item Edit item
Provide Feedback